Edgewater Capital Partners Invests in GL CHEMTEC

08.11.2022

For almost 20 years, GL CHEMTEC ("GLC") has been a leading chemistry-based CRO supporting the pharmaceutical industry and broader Life Sciences sector. GLC specializes in advanced multi-step organic synthesis, process R&D, and scale-up services to support API development, as well as advanced materials for medical devices, drug delivery, and other Life Science applications. GLC has a particular focus on the development of new bio-based materials inspired by the 12 Principles of Green Chemistry. Operating from two modern, North American-based facilities, GLC has the experience and capabilities to deliver materials ranging from milligrams to hundreds of kilos. GLC is the partner of choice from small emerging biotechs to Big Pharma and other Life Science organizations, and is recognized for its speed and client-centric business model. For more information on GLC, visit www.glchemtec.ca.